Table of Contents Author Guidelines Submit a Manuscript
Journal of Analytical Methods in Chemistry
Volume 2017, Article ID 5187084, 10 pages
https://doi.org/10.1155/2017/5187084
Research Article

UPLC-Tandem Mass Spectrometry Method for Simultaneous Determination of Fluoxetine, Risperidone, and Its Active Metabolite 9-Hydroxyrisperidone in Plasma: Application to Pharmacokinetics Study in Rats

1Pharmaceutical Chemistry Department and Drug Bioavailability Laboratory, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
2Drug Bioavailability Center, National Organization for Drug Control and Research, P.O. Box 29, Cairo, Egypt

Correspondence should be addressed to Nisreen F. Abo-Talib; moc.oohay@37_neersin

Received 6 February 2017; Accepted 24 April 2017; Published 1 June 2017

Academic Editor: Christos Kontoyannis

Copyright © 2017 Essam Ezzeldin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Soni, Martindale—The Complete Drug Reference, The Pharmaceutical Press, London, UK, 33rd edition, 2002. View at Publisher · View at Google Scholar
  2. J. F. Wernicke, “The side effect profile and safety of fluoxetine,” Journal of Clinical Psychiatry, vol. 46, no. 3, pp. 59–67, 1985. View at Google Scholar · View at Scopus
  3. W. Z. Pooterand and L. E. Hollister, “Antidepressant agents,” in Basic & Clinical Pharmacology, Katzung B. G., Ed., pp. 482–496, 9th edition, 2004. View at Google Scholar
  4. H. Y. Meltzer, “Mechanism of action of atypical antipsychotic drugs,” in Neuropsy Chopharmacology, K. L. Davis, J. T. Charney Coyle, and C. Nemeroff, Eds., pp. 819–831, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2002. View at Google Scholar
  5. M.-L. Huang, A. Van Peer, R. Woestenborghs et al., “Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects,” Clinical Pharmacology and Therapeutics, vol. 54, no. 3, pp. 257–268, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Heykants, M. L. Huang, G. Mannens et al., “The pharmacokinetics of risperidone in humans: a summary,” Journal of Clinical Psychiatry, vol. 55, no. 5, pp. 13–17, 1994. View at Google Scholar · View at Scopus
  7. F. Bueno, A. M. Bergold, and P. E. Fröehlich, “Assay of fluoxetine hydrochloride by titrimetric and HPLC methods,” Bollettino Chimico Farmaceutico, vol. 139, no. 6, pp. 256–259, 1999. View at Google Scholar · View at Scopus
  8. M. Shamsipur, L. S. Dastjerdi, S. Haghgoo, D. Armspach, D. Matt, and H. Y. Aboul-Enein, “Chiral selectors for enantioresolution and quantitation of the antidepressant drug fluoxetine in pharmaceutical formulations by 19F NMR spectroscopic method,” Analytica Chimica Acta, vol. 601, no. 1, pp. 130–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Atta-Politou, I. Skopelitis, I. Apatsidis, and M. Koupparis, “In vitro study on fluoxetine adsorption onto charcoal using potentiometry,” European Journal of Pharmaceutical Sciences, vol. 12, no. 3, pp. 311–319, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. C. R. Shah, N. J. Shah, B. N. Suhagia, and N. M. Patel, “Simultaneous assay of olanzapine and fluoxetine in tablets by column high-performance liquid chromatography and high-performance thin-layer chromatography,” Journal of AOAC International, vol. 90, no. 6, pp. 1573–1578, 2007. View at Google Scholar · View at Scopus
  11. N. Yilmaz, Y. Özkan, S. A. Özkan, I. Biryol, and H. Y. Aboul-Enein, “High performance liquid chromatographic assay and drug dissolution studies of fluoxetine hydrochloride in capsule formulations,” Journal of Liquid Chromatography and Related Technologies, vol. 23, no. 11, pp. 1699–1710, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Raggi, G. Casamenti, R. Mandrioli, C. Sabbioni, and V. Volterra, “A rapid LC method for the identification and determination of CNS drugs in pharmaceutical formulations,” Journal of Pharmaceutical and Biomedical Analysis, vol. 23, no. 1, pp. 161–167, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. M. T. Maya, C. R. Domingos, M. T. Guerreiro, and J. A. Morais, “Determination of the antidepressant fluoxetine in human plasma by LC with UV detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 23, no. 6, pp. 989–996, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Lucca, G. Gentilini, S. Lopez-Silva, and A. Soldarini, “Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography,” Therapeutic Drug Monitoring, vol. 22, no. 3, pp. 271–276, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. J. J. Berzas Nevado, M. J. Villaseñor Llerena, A. M. Contento Salcedo, and E. Aguas Nuevo, “Determination of fluoxetine, fluvoxamine, and clomipramine in pharmaceutical formulations by capillary gas chromatography,” Journal of Chromatographic Science, vol. 38, no. 5, pp. 200–206, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Lacassie, J.-M. Gaulier, P. Marquet, J.-F. Rabatel, and G. Lachâtre, “Methods for the determination of seven selective serotonin reuptake inhibitors and three active metabolites in human serum using high-performance liquid chromatography and gas chromatography,” Journal of Chromatography B: Biomedical Sciences and Applications, vol. 742, no. 2, pp. 229–238, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J. J. Berzas Nevado, A. M. Contento Salcedo, M. J. Villaseñor Llerena, and E. Aguas Nuevo, “Method development and validation for the simultaneous determination of fluoxetine and fluvoxamine in pharmaceutical preparations by capillary electrophoresis,” Analytica Chimica Acta, vol. 417, no. 2, pp. 169–176, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Buzinkaiová and J. Polonský, “Determination of four selective serotonin reuptake inhibitors by capillary isotachophoresis,” Electrophoresis, vol. 21, no. 14, pp. 2839–2841, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Titier, S. Bouchet, F. Péhourcq, N. Moore, and M. Molimard, “High-performance liquid chromatographic method with diode array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 788, no. 1, pp. 179–185, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Raggi, F. Bugamelli, C. Sabbioni, M. A. Saracino, and C. Petio, “HPLC-DAD determination of plasma levels of the antipsychotic risperidone and its main metabolite for toxicological purposes,” Journal of Separation Science, vol. 28, no. 3, pp. 245–250, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Mahatthanatrakul, T. Nontaput, S. Sriwiriyajan, W. Ridtitid, and M. Wongnawa, “Bioequivalence study of a generic risperidone (Iperdal®) in healthy Thai male volunteers,” Journal of Science and Technology, vol. 30, no. 3, pp. 307–312, 2008. View at Google Scholar · View at Scopus
  22. A. Avenoso, G. Facciolà, M. Salemi, and E. Spina, “Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection,” Journal of Chromatography B: Biomedical Sciences and Applications, vol. 746, no. 2, pp. 173–181, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Saracino, A. de Palma, G. Boncompagni, and M. A. Raggi, “Analysis of risperidone and its metabolite in plasma and saliva by LC with coulometric detection and a novel MEPS procedure,” Talanta, vol. 81, no. 4-5, pp. 1547–1553, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Locatelli, A. Mrhar, and I. Grabnar, “Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 50, no. 5, pp. 905–910, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. E. Balant-Gorgia, M. Gex-Fabry, C. Genet, and L. P. Balant, “Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors,” Therapeutic Drug Monitoring, vol. 21, no. 1, pp. 105–115, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. B. M. M. Remmerie, L. L. A. Sips, R. De Vries et al., “Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 783, no. 2, pp. 461–472, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. M. Lostia, L. Mazzarini, I. Pacchiarotti et al., “Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response,” Therapeutic Drug Monitoring, vol. 31, no. 4, pp. 475–481, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. De Meulder, B. M. M. Remmerie, R. de Vries et al., “Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 870, no. 1, pp. 8–16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Bhatt, G. Subbaiah, and S. Singh, “Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma,” Rapid Communications in Mass Spectrometry, vol. 20, no. 14, pp. 2109–2114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. Z. Rogóz, G. Skuza, W. A. Daniel, J. Wójcikowski, D. Dudek, and A. Wróbel, “Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression,” Pharmacological Reports, vol. 59, no. 6, pp. 778–784, 2007. View at Google Scholar · View at Scopus
  31. N. Mueller, “COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence,” Current Opinion in Investigational Drugs, vol. 11, no. 1, pp. 31–34, 2010. View at Google Scholar
  32. K. Rasmussen, “Creating more effective antidepressants: clues from the clinic,” Drug Discovery Today, vol. 11, no. 13-14, pp. 623–631, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Yoshimura, W. Umene-Nakano, N. Ueda, A. Ikenouchi-Sugita, H. Hori, and J. Nakamura, “Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline,” Human Psychopharmacology: Clinical and Experimental, vol. 23, no. 8, pp. 707–713, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. G. I. Keitner, S. J. Garlow, C. E. Ryan et al., “A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression,” Journal of Psychiatric Research, vol. 43, no. 3, pp. 205–214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation, May 2001.